{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:01:24Z","timestamp":1790452884478,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.medj.2024.06.013","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T14:53:06Z","timestamp":1721227986000},"page":"1282-1292.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial"],"prefix":"10.1016","volume":"5","author":[{"given":"Suad","family":"Hannawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph Elvi","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlina","family":"Burhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Dovie","family":"Lallaine Borra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace P.","family":"Aquitania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake Warren C.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelza","family":"Mae A. Zabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Camilo C.","family":"Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta","family":"Zoleta-De Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Feng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.06.013_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-COV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.medj.2024.06.013_bib2","article-title":"Neutralization against XBB.1 and XBB.1.5 after Omicron subvariants breakthrough infection or reinfection","volume":"33","author":"Chen","year":"2023","journal-title":"Lancet Reg. Health. West. Pac."},{"key":"10.1016\/j.medj.2024.06.013_bib3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(23)00070-1","article-title":"Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.medj.2024.06.013_bib4","series-title":"Weekly epidemiological update on COVID-19-30 March 2023","year":"2023"},{"key":"10.1016\/j.medj.2024.06.013_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","article-title":"Low neutralization of SARS-COV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","volume":"29","author":"Kurhade","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41423-023-00988-0","article-title":"Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-COV-2 lineage XBB.1.5","volume":"20","author":"Hoffmann","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.medj.2024.06.013_bib7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1056\/NEJMc2214314","article-title":"Substantial neutralization escape by SARS-COV-2 omicron variants BQ.1.1 and XBB.1","volume":"388","author":"Miller","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.medj.2024.06.013_bib9","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of covid-19 mRNA vaccine against Omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib10","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1473-3099(23)00199-8","article-title":"Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged \u226518 years: A randomised, double-blind, phase 2B trial","volume":"23","author":"Wu","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.medj.2024.06.013_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.medj.2024.06.013_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijid.2022.01.030","article-title":"Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (delta) variant\u2013infected patients in Jiangsu, China","volume":"116","author":"Hu","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.medj.2024.06.013_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.917732","article-title":"Effectiveness and cost-effectiveness of inactivated vaccine to address COVID-19 pandemic in China: Evidence from Randomized Control Trials and real-world studies","volume":"10","author":"Fu","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.medj.2024.06.013_bib14","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-022-30340-5","article-title":"Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-COV-2 Omicron variant","volume":"13","author":"Zuo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2024.06.013_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","article-title":"Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting","volume":"625","author":"Yisimayi","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.medj.2024.06.013_bib16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.medj.2024.06.013_bib17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41392-021-00861-4","article-title":"Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.medj.2024.06.013_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41421-023-00609-0","article-title":"Neutralization of Omicron XBB.1 by booster vaccination with BA.4\/5 monovalent mRNA vaccine","volume":"10","author":"Zhao","year":"2024","journal-title":"Cell Discov."},{"key":"10.1016\/j.medj.2024.06.013_bib19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41467-023-36110-1","article-title":"Efficacy of an unmodified bivalent mRNA vaccine against SARS-COV-2 variants in female small animal models","volume":"14","author":"Corleis","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2024.06.013_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-022-01105-9","article-title":"Origin, virological features, immune evasion and intervention of SARS-COV-2 Omicron sublineages","volume":"7","author":"Xia","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.medj.2024.06.013_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-COV-2 delta and Omicron variants following heterologous CORONAVAC plus BNT162B2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib22","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","article-title":"Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA. 5 Omicron variant in mice","volume":"29","author":"Scheaffer","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1056\/NEJMc2214293","article-title":"Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster","volume":"388","author":"Davis-Gardner","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.medj.2024.06.013_bib26","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2024.06.013_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102231","article-title":"Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: A double-blinded, randomised, controlled, phase 3b trial","volume":"64","author":"Liu","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.medj.2024.06.013_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1473-3099(23)00010-5","article-title":"ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5","volume":"23","author":"Yue","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.medj.2024.06.013_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41422-023-00781-8","article-title":"Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection","volume":"33","author":"Gao","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.medj.2024.06.013_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/vaccines9080825","article-title":"Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis","volume":"9","author":"Bignucolo","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.medj.2024.06.013_bib31","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1080\/21645515.2021.1984135","article-title":"Is there a difference in the efficacy of COVID-19 vaccine in males and females? - A systematic review and meta-analysis","volume":"17","author":"Zhu","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.medj.2024.06.013_bib32","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.abm8108","article-title":"The immunology and immunopathology of COVID-19","volume":"375","author":"Merad","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.medj.2024.06.013_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/14760584.2023.2174529","article-title":"Understanding the mechanisms for COVID-19 vaccine's protection against infection and severe disease","volume":"22","author":"Yang","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.medj.2024.06.013_bib34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.abg9857","article-title":"Scent of a vaccine","volume":"373","author":"Lund","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.medj.2024.06.013_bib35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib36","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162B2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.06.013_bib37","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet. Microbe"},{"key":"10.1016\/j.medj.2024.06.013_bib38","series-title":"Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials","year":"2007"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024002599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T15:50:27Z","timestamp":1728661827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024002599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666634024002599"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.06.013","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}